Roche's Actemra/RoActemra (tocilizumab) Receives the US FDA's EUA for Hospitalized Patients with COVID-19
Shots:
- The US FDA has issued a EUA for Actemra/RoActemra to treat COVID-19 in hospitalized adults & pediatric patients aged >2 yrs. who are receiving systemic corticosteroids & require supplemental oxygen- non-invasive or invasive mechanical ventilation- or ECMO
- The EUA is based on results from 4 controlled studies i.e COVACTA- EMPACTA- REMDACTA & RECOVERY that evaluates Actemra/RoActemra (IV) in 5-500+ hospitalized patients with COVID-19. The studies suggest that the therapy may improve outcomes in patients with no new safety signals identified
- Actemra/RoActemra is the 1st approved IL-6 receptor antagonist for patients with moderate-to-severe active RA
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com